tiprankstipranks
The Fly

Guggenheim ups Tarsus Pharmaceuticals price target, would buy on weakness

Guggenheim ups Tarsus Pharmaceuticals price target, would buy on weakness

Guggenheim raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $78 from $75 and keeps a Buy rating on the shares. The firm was “a bit puzzled by the negative stock reaction following what we see as strong results and a solid guide,” notes the analyst, who recommends investors to be buyers on the weakness.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com